Recent Finacing
Recent Raise
AnHeart Therapeutics is a clinical-stage biopharmaceutical developing ROS1/NTRK inhibitor taletrectinib plus mIDH1 and AXL oncology candidates, conducting global Phase 1–2 trials from offices in China and the U.S.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
